Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: penttila k. ESMO Open. 2019 Sep 8;4(5):e000570. doi: 10.1136/esmoopen-2019-000570. eCollection 2019. ESMO Open. 2019. PMID: 31555488 Free PMC article. Review.
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähteenvuo J, Penttilä K, Gisselbrecht C, Enzmann H, Pignatti F. Delgado J, et al. Among authors: penttila k. Hemasphere. 2021 Jun 28;5(7):e604. doi: 10.1097/HS9.0000000000000604. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34235401 Free PMC article. Review.
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, Garcia-Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F. Tzogani K, et al. Among authors: penttila k. Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23. Oncologist. 2021. PMID: 33179377 Free PMC article. Clinical Trial.
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Tzogani K, Penttilä K, Lapveteläinen T, Hemmings R, Koenig J, Freire J, Márcia S, Cole S, Coppola P, Flores B, Barbachano Y, Roige SD, Pignatti F. Tzogani K, et al. Among authors: penttila k. Oncologist. 2020 Sep;25(9):e1414-e1420. doi: 10.1634/theoncologist.2019-0785. Epub 2020 Apr 13. Oncologist. 2020. PMID: 32282100 Free PMC article. Review.
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
Pauwels K, Huys I, Casteels M, Larsson K, Voltz C, Penttila K, Morel T, Simoens S. Pauwels K, et al. Among authors: penttila k. Orphanet J Rare Dis. 2017 Feb 16;12(1):36. doi: 10.1186/s13023-017-0578-4. Orphanet J Rare Dis. 2017. PMID: 28209180 Free PMC article.
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Kolonen A, Sinisalo M, Huhtala H, Rimpiläinen J, Rintala H, Sankelo M, Koivunen E, Silvennoinen R, Räty R, Ruutu T, Volin L, Porkka K, Jantunen E, Nousiainen T, Kuittinen T, Penttilä K, Pyörälä M, Säily M, Koistinen P, Kauppila M, Itälä-Remes M, Ollikainen H, Rauhala A, Kairisto V, Pelliniemi TT, Elonen E; Finnish Leukemia Group. Kolonen A, et al. Among authors: penttila k. Eur J Haematol. 2022 Sep;109(3):257-270. doi: 10.1111/ejh.13805. Epub 2022 Jun 14. Eur J Haematol. 2022. PMID: 35634931 Clinical Trial.
Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
Turunen A, Silvennoinen R, Partanen A, Valtola J, Siitonen T, Putkonen M, Sankelo M, Pyörälä M, Kuittinen T, Penttilä K, Sikiö A, Savolainen ER, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Turunen A, et al. Among authors: penttila k. Transfusion. 2021 Jun;61(6):1830-1844. doi: 10.1111/trf.16424. Epub 2021 May 6. Transfusion. 2021. PMID: 33955591 Free article. Clinical Trial.
Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
Partanen A, Turunen A, Valtola J, Pyörälä M, Vasala K, Kuittinen O, Kuitunen H, Penttilä K, Keskinen L, Kuittinen T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Partanen A, et al. Among authors: penttila k. Transfusion. 2021 Feb;61(2):516-525. doi: 10.1111/trf.16198. Epub 2020 Nov 27. Transfusion. 2021. PMID: 33245582 Clinical Trial.
65 results